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Abstract 
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- SIGNIFICANCE OF NIGRAL AND STRIATAL DOPAMINE RELEASE 
IN NORMAL, HEMIPARKINSONIAN AND DYSKINETIC RATS 
 
 
Introduction: The nigrostriatal dopamine (DA) containing neurones are a pivotal component in the 
basal ganglia, a network that regulates movement. Degeneration of these neurones causes the 
cardinal symptoms of Parkinson’s disease (PD). In addition to releasing DA from terminals in the 
striatum, these neurones also release DA from cell bodies and dendrites in the substantia nigra (SN). 
Although, somatodendritic DA release is known to influence motor performance, the mechanisms 
for this regulation needs to be clarified. PD is predominantly treated with L-DOPA, a precursor of 
DA. After 4-6 years of L-DOPA-treatment, approximately 40 % of the PD patients develop side 
effects in the form of abnormal involuntary movements. The reasons for these abnormal movements 
are not yet fully elucidated, but they are believed to be induced by large pulsatile fluctuations of DA 
following L-DOPA administration.  Methods and observations: By use of simultaneous nigral and 
striatal microdialysis combined with motor performance testing, we demonstrate that nigral 
somatodendritic DA release exerts its influence on motor performance without affecting striatal 
terminal release. We also show that somatodendritic DA release can functionally compensate for 
disturbances in striatal DA release and thus partially maintain motor ability. Furthermore, local nigral 
application of the muscarinic antagonist scopolamine amplifies a previously described motor activity-
related increase in somatodendritic DA release, and this amplification partially restores motor 
performance ability in 6-OHDA-hemilesioned rats. By combining dual probe microdialysis with a rat 
model of L-DOPA-induced dyskinesias, we demonstrate that the amount of DA formed and 
released from a given dose of L-DOPA is larger in rats that express dyskinesias than in rats that do 
not. Furthermore, our data indicate that the larger DA peak in dyskinetic compared to non-
dyskinetic animals reflects a denser serotonergic innervation in the former group. We also show that 
5-HT autoreceptor agonists attenuate extracellular DA concentrations following L-DOPA and 
reduce dyskinesias. Conclusions: The results in this thesis indicate that the principal role of 
somatodendritic DA release is to modulate basal ganglia output on the level of the substantia nigra, 
and not to regulate terminal release in the striatum. Moreover, our findings indicate that the amount 
of DA formed from an L-DOPA dose is the main cause of dyskinesias in rats, and also lend support 
to previous findings identifying striatal 5-HT neurones as the source of L-DOPA-derived DA. 
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